AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR for Asthma

 AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR for Asthma AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR for Asthma

AstraZeneca and Amgen Report Results of Tezepelumab in P-III NAVIGATOR for Asthma

Shots:

  • The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO + SOC in adults (18–80yrs.) & adolescents (12–17yrs.) with severe, uncontrolled asthma, who were receiving treatment with medium/high dose ICS + at least 1 additional controller medication with or without OCS
  • Trial met its 1EPs i.e. reduction in AAER @52wks. in the overall population. The study also met 1EPs in patients with low levels of eosinophils i.e. <300 & 150 cells/microlitre
  • Tezepelumab is mAb that inhibits the action of TSLP and has received US FDA’s BT designation in Sept’2018 for patients with severe asthma, without an eosinophilic phenotype

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Indian Express


Post Views:
8